Results 1 to 10 of about 332,200 (286)

Second‐line therapy with first‐ or second‐generation tyrosine kinase inhibitors in EGFR‐mutated non‐small cell lung cancer patients with T790M‐negative or unidentified mutation

Thoracic Cancer, 2021
Background T790M mutation causes resistance to tyrosine kinase inhibitors (TKIs) in approximately 49% of patients with epidermal growth receptor‐mutant non‐small cell lung cancer (NSCLC).
Tadashi Nishimura, Tomohito Okano, Masahiro Naito, Soichi Iwanaka, Ayaka Ohiwa, Yasumasa Sakakura, Taro Yasuma, Hajime Fujimoto, Corina N. D'Alessandro‐Gabazza, Yasuhiro Oomoto, Tetsu Kobayashi, Esteban C. Gabazza, Hidenori Ibata   +12 more
doaj   +1 more source

An EGFR T790M-mutated lung adenocarcinoma undergoing large-cell neuroendocrine carcinoma transformation after osimertinib therapy: a case report

Journal of Medical Case Reports, 2020
Background Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor, is selective for both epidermal growth factor receptor tyrosine kinase inhibitor–sensitizing and T790M resistance mutations.
Shinichi Miyazaki, Yasumasa Kuno, Shunsaku Hayai, Ryo Teramachi, Ryo Yamashita, Yusuke Saito, Kosuke Higuchi, Yoshiharu Nara, Takuya Ikeda   +8 more
doaj   +1 more source

Simultaneous Presence of Acetylcholine Receptor and Muscle Specific Tyrosine Kinase Antibodies in Myasthenia Gravis [PDF]

International Journal of Basic Science in Medicine, 2019
Myasthenia gravis (MG) is known as an autoimmune disorder which affects transmission in neuromuscular junction. The serologic tests used for diagnosis include acetylcholine receptor and muscle specific receptor tyrosine kinase antibodies.
Maryam Poursadeghfard, Sara Azhdari
doaj   +1 more source

The deleted in brachydactyly B domain of ROR2 is required for receptor activation by recruitment of Src. [PDF]

PLoS ONE, 2008
The transmembrane receptor 'ROR2' resembles members of the receptor tyrosine kinase family of signalling receptors in sequence but its' signal transduction mechanisms remain enigmatic.
Shiva Akbarzadeh, Lee M Wheldon, Steve M M Sweet, Sonia Talma, Faraz Khosravi Mardakheh, John K Heath   +5 more
doaj   +1 more source

Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials

Technology in Cancer Research & Treatment, 2020
Background: The efficacy of next-generation epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer who have failed first-generation epidermal growth factor receptor-tyrosine kinase inhibitors ...
Yi-Tian Qi MM, Yi Hou PhD, Liang-Chen Qi MD   +2 more
doaj   +1 more source

The Relationship between IGF Pathway and Acquired Resistance to Tyrosine Kinase Inhibitors in Cancer Therapy

Frontiers in Bioscience-Landmark, 2023
The tyrosine kinase signaling pathway is an important pathway for cell signal transduction, and is involved in regulating cell proliferation, cell cycle, apoptosis and other essential biological functions.
Yanjing Peng, Jinjing Tan
doaj   +1 more source

Crystal structure of the kinase domain of a receptor tyrosine kinase from a choanoflagellate, Monosiga brevicollis.

PLoS ONE, 2023
Genomic analysis of the unicellular choanoflagellate, Monosiga brevicollis (MB), revealed the remarkable presence of cell signaling and adhesion protein domains that are characteristically associated with metazoans. Strikingly, receptor tyrosine kinases,
Teena Bajaj, John Kuriyan, Christine L Gee   +2 more
doaj   +1 more source

ISOLATION AND CHARACTERIZATION OF INSULIN RECEPTOR OF PLASMA MEMBRANES OF RAT LIVER CELLS AT MODEL OF TYPE 2 DIABETES [PDF]

Biotechnologia Acta, 2014
The insulin receptor was isolated from the liver cell membranes of control and diabetic rats. The protein purity was controlled by electrophoresis and Western blot.
T. I. Halenova, M. Y. Kuznetsova, O. M. Savchuk, L. I. Ostapchenko   +3 more
doaj   +1 more source

Construction of a circRNA-miRNA-mRNA Regulated Pathway Involved in EGFR-TKI Lung Adenocarcinoma Resistance

Technology in Cancer Research & Treatment, 2021
Objectives: Epidermal growth factor receptor-tyrosine kinase inhibitors are widely used for lung epidermal growth factor receptor-positive lung adenocarcinomas, but acquired resistance is inevitable.
Chenyue Dai MM, Bing Liu MD, Shaolei Li PhD, Yang Hong PhD, Jiahui Si PhD, Ying Xiong MSc, Nan Wu MD, Yuanyuan Ma PhD   +7 more
doaj   +1 more source

Resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer patients: A meta‐analysis

Thoracic Cancer, 2021
Background Differences in the resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in patients with non‐small cell lung cancer (NSCLC) harboring epidermal growth factor receptor mutations are unknown.
Nobuaki Kobayashi, Seigo Katakura, Chisato Kamimaki, Kohei Somekawa, Nobuhiko Fukuda, Katsushi Tanaka, Keisuke Watanabe, Nobuyuki Horita, Yu Hara, Hongmei Piao, Takeshi Kaneko   +10 more
doaj   +1 more source